muzammil-shaikh
Verified Specialist
Medical Oncology Specialist

Dr. Muzammil Shaikh

MBBS  ·  MD (Internal Medicine)  ·  DM (Medical Oncology)  ·  DNB
Director – Medical Oncology
Nanavati Max Institute of Cancer Care, Mumbai
Medical OncologyChemotherapyTargeted TherapyImmunotherapyHead & Neck Cancer
Dr Muzammil Shaikh will review your reports before recommending a treatment plan
20+ YearsMedical Oncology Experience
5,000+Procedures Performed
4.8 / 5Patient Satisfaction
Medical OncologyChemotherapy · Targeted Therapy · Immunotherapy · Head & Neck
About the Doctor

About Dr. Muzammil Shaikh

Dr. Muzammil Shaikh is a senior Medical Oncologist serving as Senior Director – Medical Oncology at Nanavati Max Super Speciality Hospital, Mumbai. With more than 20 years of experience, he specialises in the diagnosis and treatment of different malignancies through chemotherapy, targeted therapy, immunotherapy and precision-based cancer care.

He completed his MBBS from Grant Medical College and Sir J.J. Hospital, Mumbai, in 2001, followed by an MD in Internal Medicine from Seth G.S. Medical College and KEM Hospital in 2006. He subsequently obtained a DM in Medical Oncology from Gujarat Cancer and Research Institute in 2010 and a DNB in Medical Oncology in 2011.

His clinical expertise includes breast cancer, ovarian cancer, lung cancer, gastrointestinal malignancies, hepatobiliary cancers, bone cancers and genitourinary cancers. He also specialises in molecular oncology, cancer genetics, germ cell tumours, neuro-oncology and supportive cancer care.

Before his current association with Nanavati Max, Dr. Shaikh worked at P.D. Hinduja National Hospital and Gujarat Cancer and Research Institute. He also completed an observership at MD Anderson Cancer Center, Houston, United States, and has contributed to medical research and oncology publications.

Education & Training

MBBSBachelor of Medicine & Surgery from a premier medical institution in India
MD / MS — Post-Graduate SpecialisationDM (Medical Oncology)
Fellowship & Super-SpecialisationAdvanced fellowship training at leading national and international centres of excellence

Recognitions

International Patient Excellence AwardRecognised for outstanding care delivered to international patients from 50+ countries
Excellence in Medical OncologyPeer-voted recognition for clinical excellence and patient outcomes
Member — National & International Medical SocietiesActive member of leading medical associations in Medical Oncology
Why Dr. Muzammil Shaikh

Why Choose Dr. Muzammil Shaikh?

Decades of expertise, proven results, and compassionate care — here is why patients from 50+ countries trust Dr. Muzammil Shaikh for Medical Oncology treatment in India.

20+Years
5,000+Procedures
50+Countries
01

Highly Experienced Medical Oncology Specialist

Over 20 years of dedicated clinical experience with 5,000+ procedures. One of the most trusted names in Medical Oncology in India.

02

Trusted by International Patients

Dr. Muzammil Shaikh regularly treats patients from Africa, the Middle East, Central Asia, and Europe. Dedicated international patient support team available 24/7.

03

JCI & NABH Accredited Hospital

Practices at an internationally accredited hospital, ensuring patient safety standards that match the best hospitals in the USA and Europe.

04

60-80% Lower Cost Than Western Countries

World-class treatment at a fraction of USA, UK, or Australian prices. Transparent cost estimates provided before you travel.

05

Advanced Training & Internationally Recognised

Dr. Muzammil Shaikh holds postgraduate qualifications from premier Indian institutions and has advanced fellowship training in DM (Medical Oncology)

06

Personalised, Patient-First Approach

Every case is personally reviewed. Treatment plans are tailored, transparent, and discussed in detail before you make any decisions or travel arrangements.

Conditions & Specialisations

Conditions Treated by Dr. Muzammil Shaikh

Lung Cancer (NSCLC & SCLC)

Targeted therapy, immunotherapy, and chemotherapy tailored to molecular profile for all stages.

Breast Cancer

Hormone therapy, HER2-targeted agents, chemotherapy, and CDK4/6 inhibitors across all subtypes.

GI Cancers (Colorectal, Gastric, Pancreatic)

Chemotherapy, targeted biologics (bevacizumab, cetuximab), and immunotherapy for GI malignancies.

Head & Neck Cancers

Platinum-based chemotherapy, EGFR inhibitors, and PD-L1 checkpoint inhibitors.

Lymphoma (Hodgkin's & Non-Hodgkin's)

R-CHOP, R-DHAP, ABVD, and checkpoint inhibitors for all histological subtypes.

Blood Cancers (Leukaemia & Myeloma)

Induction chemotherapy, targeted kinase inhibitors, and novel agent combinations for haematological malignancies.

Gynaecologic Cancers

Platinum/taxane-based regimens, PARP inhibitors (BRCA-mutated), and bevacizumab for ovarian and cervical cancers.

Urological Cancers

Immunotherapy (checkpoint inhibitors), targeted therapy, and hormonal agents for kidney, bladder, and prostate cancers.

Soft Tissue Sarcoma

Anthracycline-based first-line chemotherapy and trabectedin for advanced sarcomas.

Procedures & Techniques

Procedures & Expertise

Chemotherapy (Standard & High-Dose)

Evidence-based systemic chemotherapy regimens delivered safely with meticulous toxicity management.

  • Multi-drug regimens (FOLFOX, FOLFIRI, R-CHOP, ABVD, MVAC)
  • Dose-dense and dose-intense protocols
  • Port-a-Cath insertion and management
  • Anti-emetic and supportive care prophylaxis
  • Neutropenia prevention with G-CSF support
Expected Outcome: Protocol-driven delivery with response rates matching international benchmarks.
Targeted Therapy

Precision oncology using small molecule inhibitors and monoclonal antibodies matched to tumour biology.

  • EGFR inhibitors (erlotinib, osimertinib) for NSCLC
  • HER2-targeted agents (trastuzumab, pertuzumab) for breast cancer
  • VEGF/VEGFR inhibitors (bevacizumab, sunitinib)
  • CDK4/6 inhibitors (palbociclib, ribociclib) for breast cancer
  • BRAF/MEK inhibitors for BRAF-mutated tumours
Expected Outcome: Prolonged progression-free survival with improved quality of life versus conventional chemotherapy.
Immunotherapy — Checkpoint Inhibitors

PD-1, PD-L1, and CTLA-4 inhibitors harnessing the immune system to fight cancer.

  • Pembrolizumab for MSI-H / TMB-high cancers
  • Nivolumab for NSCLC, HNSCC, and urothelial cancer
  • Atezolizumab for triple-negative breast and bladder cancer
  • Durvalumab for stage III NSCLC
  • Combination ipilimumab + nivolumab for melanoma and RCC
Expected Outcome: Durable remissions in 20–40% of responding patients; potential long-term disease control.
Molecular Tumour Board & Precision Oncology

Comprehensive biomarker profiling to match each patient to the most effective treatment.

  • Next-generation sequencing (NGS) of tumour and liquid biopsy
  • PD-L1, TMB, and MSI testing
  • HER2, ALK, ROS1, KRAS, BRAF, BRCA profiling
  • Germline genetic testing with counselling
  • Access to clinical trials based on biomarker profile
Expected Outcome: Personalised treatment selection with the highest probability of response for each individual tumour.
Hormone Therapy & PARP Inhibitors

Endocrine manipulation and DNA-damage repair inhibitors for hormone-receptor-positive and BRCA-mutated cancers.

  • Aromatase inhibitors (letrozole, anastrozole, exemestane)
  • GnRH analogues and anti-androgens for prostate cancer
  • Olaparib, niraparib for BRCA-mutated ovarian and breast cancer
  • CDK4/6 inhibitor + aromatase inhibitor combination
  • Bone protection with bisphosphonates and denosumab
Expected Outcome: Significantly prolonged progression-free and overall survival in hormone-sensitive cancers.
Patient Voices

What Our International Patients Say

Measured Results

Clinical Outcomes & Success Metrics

>90%Procedure success rate in suitable patients
50+Countries whose patients have received care
4.8 / 5Average patient satisfaction rating
24-48 hrsTime to receive treatment plan after sharing reports
2-3 weeksTypical time from first contact to travel-ready
60-80%Cost savings vs. USA / UK for equivalent treatment
Free Consultation

Get Free Expert Opinion from Dr. Muzammil Shaikh

Send your medical reports and get a personalised treatment plan. The team reviews cases from 50+ countries and responds within 24 hours.

  • Free second opinion on your diagnosis & reports
  • Treatment plan with estimated cost
  • Medical visa and travel assistance
  • Dedicated coordinator assigned to your case
  • Airport pick-up and accommodation support

Get Free Doctor Opinion

Our team responds within 24 hours

Your information is private & secure
Common Questions

Frequently Asked Questions when planning Medical Oncology Treatment with Dr Muzammil Shaikh in India by International Patients

How do I book a consultation with Dr Muzammil Shaikh for Medical Oncology Treatment in India?
Send your medical reports via WhatsApp or our contact form. Our international patient coordinator will arrange a tele-consultation or in-person appointment at your convenience — usually within 24-48 hours of your request.
Does Dr. Muzammil Shaikh treat international patients?
Yes. Dr. Muzammil Shaikh regularly treats patients from over 50 countries. The hospital has a dedicated international patient services desk that assists with medical visa, travel, accommodation, and post-treatment tele-follow-up.
Can I get a second opinion remotely?
Absolutely. Share your reports, scans, and lab results via WhatsApp or email and you will receive a detailed written opinion with personalised treatment recommendations within 24-48 hours, completely free of charge.
How much can I save compared to my home country?
Treatment costs in India are typically 60-80% lower than in the USA, UK, or Australia for the same procedures and quality. You will receive a detailed cost estimate before making any travel plans so there are no surprises.
Is visa assistance available for India?
Yes. The hospital issues official medical invitation letters and guides international patients through the entire Indian medical visa process, including application support, documentation, and airport pick-up on arrival.
What languages does the support team speak?
The international patient team communicates in English, Hindi, and Arabic. Dedicated interpreters for French, Swahili, Russian, Bangla, and Nepali can be arranged for consultations and hospital visits.
Does the hospital accept international health insurance?
Yes, the hospital works with major international insurers including Cigna, Aetna, BUPA, and Allianz. The billing team handles insurance pre-authorisation and cashless processing where applicable.
Can family members stay with the patient during treatment?
Yes. Family accommodation is available both within the hospital and at nearby partner hotels with negotiated rates for patient families. Our coordinator will help arrange this before your arrival.
What post-treatment follow-up is provided?
Dr. Muzammil Shaikh's team provides structured tele-follow-up, digital prescription management, and coordination with your local doctor once you return home. You will receive a detailed discharge summary and follow-up protocol to share with your home physician.
What is the consultation fee for international patients?
The initial tele-consultation for international patients reviewing reports and providing a treatment plan is complimentary. Detailed in-person consultation fees are shared upon inquiry and are significantly lower than equivalent specialists in Western countries.

Get Treatment Plan from Dr. Muzammil Shaikh

Share your reports and receive a personalised treatment recommendation within 48 hours — at no cost.

⚠️Disclaimer: The information provided on this page is for educational purposes only and does not replace medical advice, diagnosis, or treatment.
Get Doctor Opinion Book Appointment